Paragon 28 (FNA) Reports Prelim Q4 Results

Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a range of its preliminary unaudited revenue for the fourth quarter and full-year ended December 31, 2021.

Preliminary unaudited revenue for the fourth quarter of 2021 is expected to be in a range of $42.3 to $42.7 million, reflecting growth of 20.7% to 21.8% compared to revenue of $35.1 million for the fourth quarter of 2020.

Preliminary unaudited revenue for the full-year of 2021 is expected to be in a range of $147.0 to $147.4 million, reflecting growth of 32.4% to 32.8% compared to revenue of $111.0 million for the full-year of 2020.

“Paragon 28’s innovative and comprehensive foot and ankle portfolio, along with solid execution by our teammates around the globe, enabled P28 to deliver over twenty percent revenue growth in the fourth quarter of 2021 despite Covid-19 headwinds on elective procedures,” said Albert DaCosta, Chairman and CEO of Paragon 28. “During the fourth quarter P28 also completed its IPO which improved P28’s financial strength and will further advance our mission to improve foot and ankle patient outcomes through the development and commercialization of advanced technologies, including SMART28.”

Albert DaCosta together with Paragon 28 Chief Financial Officer Steve Deitsch will be virtually presenting at the 24th Annual Needham Growth Conference on Monday, January 10th.

The presentation will be webcast live on Monday, January 10, 2022, at 2:45pm ET / 12:45pm MT. The webcast, as well as the archived recording, will be available on the investor relations section of the Company’s website at ir.paragon28.com.

You May Also Be Interested In

• ShengShu Technology explores Hong Kong IPO for over $500 million
• Needham Reiterates Buy Rating on DocGo (DCGO)
• Streamex Corp. (STEX) PT Lowered to $4 at Needham